Human Genome Epidemiology Literature Finder
Records 1 - 3 (of 3 Records) |
Query Trace: Leukopenia and BRCA1[original query] |
---|
A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study. Gynecologic oncology 2015 Jun 137 (3): 386-91. Coleman Robert L, Sill Michael W, Bell-McGuinn Katherine, Aghajanian Carol, Gray Heidi J, Tewari Krishnansu S, Rubin Steven C, Rutherford Thomas J, Chan John K, Chen Alice, Swisher Elizabeth |
Clinical outcome and toxicity from taxanes in breast cancer patients with BRCA1 and BRCA2 pathogenic germline mutations. The breast journal 2020 6 26 (8): 1572-1582. Bayraktar Soley, Zhou Jade Z, Bassett Roland, Gutierrez Barrera Angelica M, Layman Rachel M, Valero Vicente, Arun Ba |
Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2021 Sep . Westin Shannon N, Labrie Marilyne, Litton Jennifer K, Blucher Aurora, Fang Yong, Vellano Christopher P, Marszalek Joseph R, Feng Ningping, Ma XiaoYan, Creason Allison, Fellman Bryan, Yuan Ying, Lee Sanghoon, Kim Tae-Beom, Liu Jinsong, Chelariu-Raicu Anca, Chen Tsun Hsuan, Kabil Nashwa, Soliman Pamela T, Frumovitz Michael, Schmeler Katheleen M, Jazaeri Amir, Lu Karen H, Murthy Rashmi, Meyer Larissa A, Sun Charlotte C, Sood Anil K, Coleman Robert L, Mills Gordon |
- Page last reviewed:Feb 1, 2024
- Page last updated:Apr 22, 2024
- Content source: